| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial |
Completed |
Luspatercept (ACE 536) |
3 |
ACE-536-B-THAL-001 |
King Khalid University Hospital (Riyadh) |
| Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis |
Completed |
cholecalciferol |
3 |
E-15-1667 |
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Intra Peritoneal Instillation of Ropivacaine with or without Dexmedetomidine for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy. A randomized controlled |
Completed |
Dexmedetomidine |
2 |
version 4 |
King Abdullah Medical City (Makkah) |
| Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) |
Completed |
Osimertinib (AZD9291) |
3 |
D5160C00022 |
King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Terminated |
Osimertinib (AZD9291) |
3 |
D5160C00007 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study |
Terminated |
haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) |
3 |
Version date Sep-3-2013 |
King Khalid University Hospital (Riyadh) |
| Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. |
Completed |
Doxorubicin |
3 |
BA2011/03/04 |
King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations |
Completed |
rAAV2-VMD2-hMERTK |
1 |
rAAV2-VMD2-hMERTK |
King Faisal Specialist Hospital and Research Center (Riyadh), King Khaled Eye Specialist Hospital (Riyadh) |
| "An open-label extension study of the long-term safety,tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)." |
Terminated |
Ambrisentan |
3 |
116457 |
King Fahad Medical City (Riyadh) |
| A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer |
Terminated |
Docetaxel/Cisplatin and Bevacizumab |
3 |
Version 1.3 date 6 may 2012 |
King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
